{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:13:21Z","timestamp":1791497601221,"version":"4.3.4"},"reference-count":97,"publisher":"Impact Journals, LLC","issue":"39","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,5,22]]},"DOI":"10.18632\/oncotarget.25008","type":"journal-article","created":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T06:35:34Z","timestamp":1526711734000},"page":"25738-25749","source":"Crossref","is-referenced-by-count":75,"title":["Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives"],"prefix":"10.18632","volume":"9","author":[{"given":"Jialin","family":"Duan","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Tao","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maocai","family":"Zhai","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wuhan Hospital of Integrated Traditional Chinese and Western Medicine, Wuhan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhou","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiagao","family":"Lv","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, An Zhen Hospital, Capital Medical University, Beijing, P.R. China"},{"name":"Texas Cardiac Arrhythmia Institute at St. David\u2019s Medical Center, Austin, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/157488610789869111","article-title":"Antineoplastic chemotherapy induced QTc prolongation","volume":"5","author":"Recondo","year":"2010","journal-title":"Curr Drug Saf"},{"key":"2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"key":"3","first-page":"263","article-title":"[Ventricular tachycardia with 2 variable opposing foci]. [Article in French]","volume":"59","author":"Dessertenne","year":"1966","journal-title":"Arch Mal Coeur Vaiss"},{"key":"4","first-page":"212178","article-title":"Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review","volume":"2012","author":"Vardas","year":"2012","journal-title":"Sci World J"},{"key":"5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"121","author":"Zareba","year":"2010","journal-title":"Circulation"},{"key":"6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1540-8167.2006.00408.x","article-title":"QT interval: how to measure it and what is \u201cnormal\u201d","volume":"17","author":"Zareba","year":"2006","journal-title":"J Cardiovasc Electrophysiol"},{"key":"7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.hrthm.2013.11.017","article-title":"QTc compared to JTc for monitoring drug-induced repolarization changes in the setting of ventricular pacing","volume":"11","author":"Daoud","year":"2014","journal-title":"Heart Rhythm"},{"key":"8","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/01.CIR.0000095027.28753.9D","article-title":"Prognostic significance of corrected QT and corrected JT interval for incident coronary heart disease in a general population sample stratified by presence or absence of wide QRS complex: the ARIC Study with 13 years of follow-up","volume":"108","author":"Folsom","year":"2003","journal-title":"Circulation"},{"key":"9","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/0022-0736(92)90079-F","article-title":"Should the JT rather than the QT interval be used to detect prolongation of ventricular repolarization? An assessment in normal conduction and in ventricular conduction defects","volume":"25","author":"Calhoun","year":"1992","journal-title":"J Electrocardiol"},{"key":"10","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.hrthm.2006.05.023","article-title":"Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval","volume":"3","author":"Woosley","year":"2006","journal-title":"Heart Rhythm"},{"key":"11","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.jelectrocard.2004.08.030","article-title":"A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs","volume":"37","author":"Macfarlane","year":"2004","journal-title":"J Electrocardiol"},{"key":"12","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2008.12.014","article-title":"AHA\/ACCF\/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society","volume":"53","author":"Mason","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"13","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.amjcard.2013.06.027","article-title":"Correlation of QT interval correction methods during atrial fibrillation and sinus rhythm","volume":"112","author":"Mittal","year":"2013","journal-title":"Am J Cardiol"},{"key":"14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ccep.2016.02.009","article-title":"Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients","volume":"8","author":"Darbar","year":"2016","journal-title":"Card Electrophysiol Clin"},{"key":"15","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1152\/physrev.00036.2011","article-title":"hERG K(+) channels: structure, function, and clinical significance","volume":"92","author":"Hill","year":"2012","journal-title":"Physiol Rev"},{"key":"16","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.phrs.2010.07.008","article-title":"The selective estrogen receptor modulator raloxifene inhibits cardiac delayed rectifier potassium currents and voltage-gated sodium current without QTc interval prolongation","volume":"62","author":"Li","year":"2010","journal-title":"Pharmacol Res"},{"key":"17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/01.CIR.0000109484.00668.CE","article-title":"Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents","volume":"109","author":"Roden","year":"2004","journal-title":"Circulation"},{"key":"18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-2999(00)00667-1","article-title":"The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons","volume":"406","author":"Lersch","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2796.2005.01589.x","article-title":"Long QT syndrome: reduced repolarization reserve and the genetic link","volume":"259","author":"Roden","year":"2006","journal-title":"J Intern Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/01.CIR.84.3.1136","article-title":"The long QT syndrome. Prospective longitudinal study of 328 families","volume":"84","author":"Jennifer","year":"1991","journal-title":"Circulation"},{"key":"21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1542-474X.2008.00254.x","article-title":"T-wave alternans: reviewing the clinical performance, understanding limitations, characterizing methodologies","volume":"13","author":"Garcia","year":"2008","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"22","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Dahlberg","year":"2001","journal-title":"J Clin Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2003.10.009","article-title":"Effect of arsenic trioxide on QT interval in patients with advanced malignancies","volume":"21","author":"Soignet","year":"2003","journal-title":"J Clin Oncol"},{"key":"24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.vascn.2012.03.002","article-title":"Direct effects of arsenic trioxide on action potentials in isolated cardiac tissues: importance of the choice of species, type of cardiac tissue and perfusion time","volume":"66","author":"Gallacher","year":"2012","journal-title":"J Pharmacol Toxicol Methods"},{"key":"25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/cvr\/cvs230","article-title":"Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome","volume":"96","author":"Dong","year":"2012","journal-title":"Cardiovasc Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1532\/IJH97.05056","article-title":"Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy","volume":"83","author":"Ohnishi","year":"2006","journal-title":"Int J Hematol"},{"key":"27","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1182\/blood.V97.5.1514","article-title":"Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide","volume":"97","author":"Chiaramida","year":"2001","journal-title":"Blood"},{"key":"28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2013.02.027","article-title":"\u03b1-Lipoic acid protects against arsenic trioxide-induced acute QT prolongation in anesthetized guinea pigs","volume":"705","author":"Fujimura","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1734-1140(09)70018-0","article-title":"Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron","volume":"61","author":"Gersl","year":"2009","journal-title":"Pharmacol Rep"},{"key":"30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pcad.2010.06.007","article-title":"Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?","volume":"53","author":"Lim","year":"2010","journal-title":"Prog Cardiovasc Dis"},{"key":"31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00395-006-0609-0","article-title":"Reduced repolarization reserve due to anthracycline therapy facilitates torsade de pointes induced by IKr blockers","volume":"102","author":"Eckardt","year":"2007","journal-title":"Basic Res Cardiol"},{"key":"32","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/CAD.0b013e328012d023","article-title":"QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines","volume":"18","author":"Justo","year":"2007","journal-title":"Anticancer Drugs"},{"key":"33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00210-003-0766-8","article-title":"Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen","volume":"368","author":"Karle","year":"2003","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2009.12.006","article-title":"4-Hydroxytamoxifen inhibits K(+) currents in mouse ventricular myocytes","volume":"629","author":"Fiset","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"35","doi-asserted-by":"crossref","first-page":"e78768","DOI":"10.1371\/journal.pone.0078768","article-title":"Direct, differential effects of tamoxifen, 4-hydroxytamoxifen, and raloxifene on cardiac myocyte contractility and calcium handling","volume":"8","author":"Metzger","year":"2013","journal-title":"PLoS One"},{"key":"36","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/02841860802199816","article-title":"Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma","volume":"48","author":"Lin","year":"2009","journal-title":"Acta Oncol"},{"key":"37","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejphar.2010.09.085","article-title":"Cisplatin-induced cardiotoxicity: mechanisms and cardioprotective strategies","volume":"650","author":"Radwan","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"38","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jcma.2013.05.001","article-title":"Oxaliplatin-induced acquired long QT syndrome with torsades de pointes and myocardial injury in a patient with dilated cardiomyopathy and rectal cancer","volume":"76","author":"Hsiao","year":"2013","journal-title":"J Chin Med Assoc"},{"key":"39","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3109\/0284186X.2012.762999","article-title":"Oxaliplatin-induced Torsades de pointes and long QT syndrome in a patient with gastric cancer","volume":"52","author":"Yoon","year":"2013","journal-title":"Acta Oncol"},{"key":"40","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jjco\/hyh047","article-title":"Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil\/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers","volume":"34","author":"Yilmaz","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"41","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/15563650902997831","article-title":"Life-threatening Torsades de Pointes resulting from \u201cnatural\u201d cancer treatment","volume":"47","author":"Lau","year":"2009","journal-title":"Clin Toxicol (Phila)"},{"key":"42","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1089\/acm.2012.0745","article-title":"Fatal cesium chloride toxicity after alternative cancer treatment","volume":"19","author":"Kosnett","year":"2013","journal-title":"J Altern Complement Med"},{"key":"43","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1089\/acm.2006.12.1011","article-title":"Acquired long QT syndrome secondary to cesium chloride supplement","volume":"12","author":"Ackerman","year":"2006","journal-title":"J Altern Complement Med"},{"key":"44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1460-9592.2001.00515.x","article-title":"Polymorphic ventricular tachycardia in a woman taking cesium chloride","volume":"24","author":"Niebauer","year":"2001","journal-title":"Pacing Clin Electrophysiol"},{"key":"45","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1046\/j.1460-9592.2001.00474.x","article-title":"Spontaneous, electrically, and cesium chloride induced arrhythmia and afterdepolarizations in the rapidly paced dog heart","volume":"24","author":"Li","year":"2001","journal-title":"Pacing Clin Electrophysiol"},{"key":"46","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1007\/s12032-012-0291-z","article-title":"Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: a pilot study","volume":"29","author":"Barutca","year":"2012","journal-title":"Med Oncol"},{"key":"47","first-page":"556","article-title":"The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients","volume":"137","author":"Oyan","year":"2007","journal-title":"Swiss Med Wkly"},{"key":"48","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1634\/theoncologist.2011-0445","article-title":"Administration of angiotensin-converting enzyme inhibitors and \u03b2-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?","volume":"17","author":"Tarantini","year":"2012","journal-title":"Oncologist"},{"key":"49","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/1078-0432.CCR-05-2689","article-title":"Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors","volume":"12","author":"Grever","year":"2006","journal-title":"Clin Cancer Res"},{"key":"50","first-page":"434","article-title":"QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature","volume":"19","author":"Newby","year":"2012","journal-title":"Cardiol J"},{"key":"51","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1345\/aph.1R036","article-title":"Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma","volume":"46","author":"O\u2019Bryant","year":"2012","journal-title":"Ann Pharmacother"},{"key":"52","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2174\/138920107783018417","article-title":"Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell","volume":"8","author":"Ryningen","year":"2007","journal-title":"Curr Pharm Biotechnol"},{"key":"53","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"key":"54","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3324\/haematol.2011.058776","article-title":"Clinical cardiac safety profile of nilotinib","volume":"97","author":"K\u00f6hncke","year":"2012","journal-title":"Haematologica"},{"key":"55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-3-642-54490-3_11","article-title":"Crizotinib","volume":"201","author":"Reck","year":"2014","journal-title":"Recent Results Cancer Res"},{"key":"56","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/1078-0432.CCR-09-2308","article-title":"Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2","volume":"16","author":"Kohn","year":"2010","journal-title":"Clin Cancer Res"},{"key":"57","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1200\/JCO.2010.30.9674","article-title":"A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors","volume":"28","author":"Adamson","year":"2010","journal-title":"J Clin Oncol"},{"key":"58","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00280-013-2160-7","article-title":"Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies","volume":"71","author":"Haluska","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"59","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","article-title":"Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia","volume":"30","author":"Natarajan","year":"2008","journal-title":"Clin Ther"},{"key":"60","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1158\/1078-0432.CCR-09-1521","article-title":"Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib","volume":"15","author":"Rosen","year":"2009","journal-title":"Clin Cancer Res"},{"key":"61","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","article-title":"FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements","volume":"19","author":"Pazdur","year":"2014","journal-title":"Oncologist"},{"key":"62","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1200\/JCO.2015.62.1342","article-title":"Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"63","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","article-title":"Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval)","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"64","first-page":"3243","article-title":"Cardiotoxicity of molecular-targeted drug therapy","volume":"34","author":"Yang","year":"2014","journal-title":"Anticancer Res"},{"key":"65","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1248\/bpb.b12-00778","article-title":"Blocking of the human ether-\u00e0-go-go-related gene channel by imatinib mesylate","volume":"36","author":"Du","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"66","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1742-7843.2010.00556.x","article-title":"Electrophysiological effects of the anti-cancer drug lapatinib on cardiac repolarization","volume":"107","author":"Kim","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"67","first-page":"218","article-title":"Rituximab-induced polymorphic ventricular tachycardia","volume":"37","author":"Lovell","year":"2010","journal-title":"Tex Heart Inst J"},{"key":"68","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12094-008-0201-1","article-title":"Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin\u2019s diffuse large B-cell lymphoma","volume":"10","author":"Maci\u00e1 Escalante","year":"2008","journal-title":"Clin Transl Oncol"},{"key":"69","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3816\/CLM.2008.n.035","article-title":"Acute coronary syndromes complicating the first infusion of rituximab","volume":"8","author":"Bociek","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"70","doi-asserted-by":"crossref","first-page":"288e","DOI":"10.1177\/030089161309900622","article-title":"Cardiovascular adverse events complicating the administration of rituximab: report of two cases","volume":"99","author":"Ghio","year":"2013","journal-title":"Tumori"},{"key":"71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2050-6511-14-7","article-title":"Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate","volume":"14","author":"Nguyen","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"72","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/1078-0432.CCR-0364-3","article-title":"Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer","volume":"10","author":"Remick","year":"2004","journal-title":"Clin Cancer Res"},{"key":"73","doi-asserted-by":"crossref","first-page":"E80","DOI":"10.1002\/clc.20685","article-title":"Myocardial stunning following combined modality combretastatin-based chemotherapy: two case reports and review of the literature","volume":"32","author":"Ortiz","year":"2009","journal-title":"Clin Cardiol"},{"key":"74","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/PPO.0000000000000024","article-title":"A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States","volume":"20","author":"Margolin","year":"2014","journal-title":"Cancer J"},{"key":"75","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1517\/14656566.2012.737780","article-title":"Vemurafenib for the treatment of melanoma","volume":"13","author":"Kelly","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"76","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1158\/1078-0432.CCR-06-2912","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer","volume":"13","author":"Voest","year":"2007","journal-title":"Clin Cancer Res"},{"key":"77","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jacc.2006.08.058","article-title":"The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias","volume":"49","author":"Viskin","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"78","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCEP.110.960658","article-title":"Prolonged Tpeak-to-tend interval on the resting ECG is associated with increased risk of sudden cardiac death","volume":"4","author":"Chugh","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"79","first-page":"1309","article-title":"Microvolt T-wave alternans physiological basis, methods of measurement, and clinical utility\u2014consensus guideline by International Society for Holter and Noninvasive Electrocardiology","volume":"58","author":"Rosenbaum","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"80","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.vascn.2013.01.003","article-title":"A new biomarker\u2014index of cardiac electrophysiological balance (iCEB)\u2014plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs)","volume":"68","author":"Gallacher","year":"2013","journal-title":"J Pharmacol Toxicol Methods"},{"key":"81","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40264-015-0316-6","article-title":"Pharmacogenetics of Drug-Induced QT Interval Prolongation: an Update","volume":"38","author":"Stricker","year":"2015","journal-title":"Drug Saf"},{"key":"82","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.hrthm.2007.01.019","article-title":"Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes","volume":"4","author":"Swan","year":"2007","journal-title":"Heart Rhythm"},{"key":"83","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","article-title":"Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers","volume":"81","author":"Abriel","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"84","doi-asserted-by":"crossref","first-page":"E304","DOI":"10.1002\/ijc.27348","article-title":"A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src\/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects","volume":"131","author":"Sonnichsen","year":"2012","journal-title":"Int J Cancer"},{"key":"85","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/cncr.24927","article-title":"Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors","volume":"116","author":"Chiappori","year":"2010","journal-title":"Cancer"},{"key":"86","first-page":"4027908","article-title":"Dasatinib and Prednisolone Induction Therapy for a Case of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Dilated Cardiomyopathy Accompanied by Life-Threatening Ventricular Tachycardia","volume":"2017","author":"Hino","year":"2017","journal-title":"Case Rep Hematol"},{"key":"87","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00280-014-2444-6","article-title":"Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers","volume":"73","author":"Darpo","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"88","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40264-015-0300-1","article-title":"Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk\/Benefit","volume":"38","author":"Morganroth","year":"2015","journal-title":"Drug Saf"},{"key":"89","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Dunphy","year":"2016","journal-title":"Lancet Oncol"},{"key":"90","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","article-title":"QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"112","author":"Choueiri","year":"2015","journal-title":"Br J Cancer"},{"key":"91","doi-asserted-by":"publisher","first-page":"35589","DOI":"10.18632\/oncotarget.5853","article-title":"What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment","volume":"6","author":"Russo","year":"2015","journal-title":"Oncotarget"},{"key":"92","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s10637-012-9893-8","article-title":"A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors","volume":"31","author":"Reyderman","year":"2013","journal-title":"Invest New Drugs"},{"key":"93","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.3109\/10428194.2012.760733","article-title":"Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia","volume":"54","author":"Blum","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"94","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cjca.2016.01.027","article-title":"Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: cardiomyopathy and Beyond","volume":"32","author":"Yeh","year":"2016","journal-title":"Can J Cardiol"},{"key":"95","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2147\/TCRM.S3960","article-title":"Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer","volume":"4","author":"Thomas","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"96","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Tsavaris","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"97","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrcardio.2010.121","article-title":"Cardiotoxicity of anticancer treatments: what the cardiologist needs to know","volume":"7","author":"Ewer","year":"2010","journal-title":"Nat Rev Cardiol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T22:46:04Z","timestamp":1661294764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.25008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":97,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2018,5,22]]}},"alternative-id":["25008","29876021"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.25008","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]}}}